Open AccessMetastatic mucinous tubular and spindle cell carcinoma of the kidney responding to nivolumab plus ipilimumab
Author(s) -
Fuchizawa Hirotaka,
Kijima Toshiki,
TakadaOwada Atsuko,
Nagashima Yoji,
Okazaki Akihito,
Yokoyama Megumi,
Nishihara Daisaku,
Ishida Kazuyuki,
Kamai Takao
Publication year - 2021
Publication title -
iju case reports
Language(s) - English
Resource type - Journals
ISSN - 2577-171X
DOI - 10.1002/iju5.12342
Subject(s) - nivolumab , ipilimumab , medicine , renal cell carcinoma , immunotherapy , immunohistochemistry , nephrectomy , pathology , immune system , immune checkpoint , clear cell , cancer research , oncology , kidney , immunology
Mucinous tubular and spindle cell carcinoma is a rare subtype of renal cell carcinoma. Little is known regarding the efficacy of systemic therapy on its metastatic form because of its rarity. Case presentation We present the case of a patient with metastatic mucinous tubular and spindle cell carcinoma who achieved durable complete remission of multiple osseous metastases after undergoing cytoreductive nephrectomy followed by combination immunotherapy (ipilimumab plus nivolumab). Immunohistochemical analyses of the primary tumor revealed the presence of the tumor‐infiltrating immune cells, including activated CD8 + T cells and PD‐L1 expression, suggesting an immunologically hot tumor. Conclusion Combination immunotherapy was a viable treatment option for this disease. Immunohistochemical analyses of the tumor‐infiltrating immune cells predicted the efficacy of immune checkpoint inhibitors against rare renal cancers.